MAR 04, 2017 2:19 PM PST

New drugs for an old bug

WRITTEN BY: Kerry Evans

Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Despite the advances of modern medicine, there are about 10 million new cases of tuberculosis each year, and over 1 million people die from it.

 

New drugs to treat tuberculosis?

 

Like many bacteria, some strains of M. tuberculosis have become resistant to traditional treatments. Luckily, researchers at the University of Warwick are working to develop new treatments for tuberculosis based on compounds produced by soil bacteria. Chemicals called sansanmycins are produced by species of Streptomyces that live in the soil.

 

The researchers generated a library of dihydrosansanmycin analogues and tested their ability to kill M. tuberculosis. They also tested how selective these drugs are - whether they are toxic to mammalian cells or other species of bacteria. Ideally, the drugs would be selective only for M. tuberculosis.

 

The group successfully isolated a subset of dihydrosansanmycins that do not harm mammalian cells (HEK293 cells) and that do not kill other bacteria. Specifically, they tested the drug against common so-called ESKAPE pathogens that often cause infections (these include E. coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Salmonella typhimurium). Surprisingly, the drug library only exhibited modest activity against E. coli and Pseudomonas aeruginosa, leaving the other bacteria unharmed.

 

So, just how do these new drugs work to kill M. tuberculosis? The researchers knew that these types of antibiotics (in the nucleoside family) were thought to inhibit an enzyme called MurX, a translocase that is involved in the synthesis of lipiI I (lipid I helps build the bacterial cell wall).

 

They used a collection of assays to measure MurX activity and found that their library of dihydrosansanmycins inhbited MurX to varying degrees (a range of 9-100% inhibition). However, those analogues that inhibited MurX were the same ones that were able to kill M. tuberculosis!

 

Then, because M. tuberculosis is an intracellular pathogen, they wanted to see if selected dihydrosansanmycins could kill intracellular M. tuberculosis. For this experiment, they infected THP-1 macrophages with M. tuberculosis, added three of the most potent dihydrosansamycin analogues, and assayed mycobacterial growth. Sure enough, all three of the drugs inhibited the growth of the intracellular bacteria!

 

Finally, they determined how stable the analogues were in human and mouse plasma and human and mouse liver microsomes. They found that each analogue of interest was stable in both plasma (with a half life of more than 7 hours) and liver microsomes (half life of over 160 min).

 

This is all great news - the researchers plan to further refine these sansanmycins into potential antibiotics.


Sources: Nature Communications, Science Daily

 

About the Author
  • Kerry received a doctorate in microbiology from the University of Arkansas for Medical Sciences.
You May Also Like
AUG 18, 2020
Microbiology
Syphilis was Spreading in Europe Before Columbus' Time
AUG 18, 2020
Syphilis was Spreading in Europe Before Columbus' Time
Syphilis is a sexually transmitted disease caused by a bacterium: Treponema pallidum subspecies pallidum. Its origins ha ...
AUG 24, 2020
Cell & Molecular Biology
A Shield Surrounds the Flexible SARS-CoV-2 Spike Protein
AUG 24, 2020
A Shield Surrounds the Flexible SARS-CoV-2 Spike Protein
Researchers know that the viruses including SARS-CoV-2 have a Spike protein that allows them to bind to receptors on hos ...
AUG 24, 2020
Microbiology
Microbes That Live on Air Alone Found Outside of Antarctica
AUG 24, 2020
Microbes That Live on Air Alone Found Outside of Antarctica
In 2017, researchers reported that they had identified microbes in Antarctica that could basically survive on only air. ...
SEP 20, 2020
Microbiology
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
SEP 20, 2020
Middle-Aged Adults Might Always be Susceptible to H3N2 Flu
People born in the late 1960s or 1970s might be perpetually susceptible to the H3N2 influenza virus, according to new re ...
NOV 16, 2020
Genetics & Genomics
Hidden Genes in the SARS-CoV-2 Genome
NOV 16, 2020
Hidden Genes in the SARS-CoV-2 Genome
It's essential for organisms to use their genomes to make proteins, and the processes of transcription and translation a ...
NOV 10, 2020
Neuroscience
Nanoparticles Pass the Blood-Brain Barrier in Zebrafish
NOV 10, 2020
Nanoparticles Pass the Blood-Brain Barrier in Zebrafish
Video:  Explains the challenges of delivering medicine to the brain, and possibly tools to pass the blood-brain bar ...
Loading Comments...